19 August 2024

Market Access for Pharmaceutical Products - Trends and Challenges

Learn about key trends in Market Access, how Market Access decisions are made, and how these decision-making frameworks affect evidence-based requirements for new health care interventions.

Market Access

You will gain skills and insight that will enable you to develop the Market Access strategy that best responds to the demands of constantly changing political climates, health care systems and emerging key influential institutions.

For all the talk about Market Access, not everyone seems to be able to define it. Who are the new key stakeholders, exactly? Is it true that it is no longer the prescribing doctor who decides which drug a patient should use? Is Market Access only about containing costs for the public budget, or are there benefits for patients and society as well?

This course is based on learning through discussion with leading international experts on Market Access.

 

 

 

 

 

 

 

 

 

 

 

 

 

On the course, you will increase your capacity to understand and deal with crucial Market Access issues. You will learn about key trends in Market Access, how Market Access decisions are made, and how these decision-making frameworks affect evidence-based requirements for new health care interventions. You will:

  • Acquire a basic market access vocabulary
  • Gain insight into the Market Access methodologies toolbox
  • Get an overview of the key challenges involved in Market Access
  • Identify the key stakeholders and their influence on the drug reimbursement and prescription process in some of the most important markets (e.g. USA, UK, Germany, Italy and France)
  • Gain an understanding of payers’ perspectives of key markets and of new reimbursement models impacting Market Access
  • Integrate skills enabling you to demonstrate product value
  • Discuss new aspects of Market Access like digital health and Value-Based Health Care

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Course directors
Janine Traulsen, Associate Professor/External Lecturer, Department of Pharmacy, University of Copenhagen
Marlene Gyldmark, Global Head Outcomes Research, Health Economics and Health Policy, Roche Diagnostics International, Diabetes Care AG, Switzerland

Other course teachers

Joerg Ruof, Professor MD, Founder European Institute of Heath Outcomes
Tove Holm-Larsen, Professor, Ghent University
Jakob Kjellberg, Professor, Health Economics
James Creeden, CEO, Creeden Consulting 
Joshua Ray, Head HEOR, Roche, Switzerland 

The course also includes additional speakers.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Course details

Duration: 5 days on campus
Dates: 19-23 August 2024
Frequency Once every year
Place: University of Copenhagen, Copenhagen, Denmark
Course fee: 23,000 DKK 

Fee includes teaching, course materials, all meals during course hours and examination.

Payment conditions

Level and credit: Master course; 3 ECTS
Examination date: Please consult the exam schedule
Application deadline: 31 May 2024
Admission: To be admitted, you must meet the admission criteria for Master of Industrial Drug Development


Course dates and application deadlines are announced via the  programme newsletter.

Download course curriculum